Roche and AstraZeneca-backed endocrine disease therapy developer Millendo will merge with publicly-listed OvaScience, raising a further $30m in the process.
US-listed fertility treatment provider OvaScience has agreed to merge with Millendo Therapeutics, a US-based endocrine disease drug developer backed by pharmaceutical companies Roche and AstraZeneca.
The unified company will take Millendo’s name and OvaScience’s stock listing on the Nasdaq Capital Market. Millendo’s investors will own 80% of the combined company and Ovascience shareholders 20%.
The all-stock deal will be boosted with $30m from investors including Roche subsidiary Roche Venture Fund.
New Enterprise Associates (NEA), Osage University Partners, Altitude Life Science…
